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ABSTRACT:
Paediatric HIV-infection rates remain high in Cameroon in spite of the various existing preventive strategies. This study will
provide scientific evidence that HIV-infected pregnant women receiving highly active triple antiretroviral therapy would be
expected to have significantly lower viral loads and a lower risk of HIV mother-to-child transmission (MTCT) without scheduled
Caesarean section. We enrolled 90 newly diagnosed HIV-infected pregnant women who accepted to participate in the study
from the 4 Teaching Hospitals in Yaoundé between January 1, 2006 and December 31, 2008. In addition to routine antenatal care,
they received two types of potent triple antiretroviral regimens depending on their initial CD4 counts. Drug efficacy and safety
were assessed by CD4 count, viral load, liver enzymes level, fasting blood sugar level, blood urea and haemoglobin concentration
level before and after treatment and the paediatric seroprevalence rate. Highly active triple antiretroviral therapy was associated
with maternal immunological improvement, statistically significant reduction of maternal viral load (P< 0.05) with resultant low
paediatric HIV infection rate (1.1%) and minimal maternal biological impairment. Short courses of highly active triple antiretroviral
therapy to prevent HIV MTCT is therefore not only efficacious compared to other treatment options like monotherapy, bitherapy,
and bitherapy associated with scheduled caesarean section, but also safe and should constitute the mainstay intervention
strategy.
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L’EFFICACITE DE LA PREVENTION DE LA TRANSMISSION MERE-ENFANT
DU VIH PAR LA TRI-THERAPIE ANTI-RETROVIRALE DANS LES HOPITAUX
UNIVERSITAIRES DE YAOUNDE, CAMEROUN.
RESUME:
Le taux d’infection pédiatrique du VIH demeure élevé au Cameroun malgré les nombreuses mesures préventives existantes. Le
but de cette étude était de prouver que les femmes enceintes séropositives recevant une trithérapie anti-rétrovirale auraient une
charge virale significativement plus faible avec en conséquence un moindre risque de transmission mère-enfant (TME) du VIH,
même en l’absence de la réalisation d’une césarienne élective. Quatre vingt dix femmes enceintes infectées par le VIH et qui
avaient accepté de participer entièrement à l’étude ont été recrutées dans les 4 hôpitaux universitaires de Yaoundé entre le 1er
janvier 2006 et le 31 décembre 2008. Elles avaient reçu l’un des 2 protocoles de trithérapie antirétrovirale en fonction de leur taux
de CD4 initial, en plus des soins prénataux de routine. L’efficacité et la tolérance des médicaments étaient évaluées par le dosage
du taux de CD4, la charge virale, le taux des enzymes hépatiques, la glycémie à jeun, l’urée sanguine, le taux d’hémoglobine, ceci
avant et après le traitement ainsi que le taux de séroprévalence pédiatrique. La trithérapie antirétrovirale était associée à une
amélioration du statut immunologique maternel, une réduction considérable de la charge virale maternelle (P< 0.05) avec une
baisse conséquente du taux d’infection pédiatrique du VIH (1.1%) et une légère perturbation des paramètres biologiques
maternels. Les cures courtes de trithérapie antirétrovirale pour la prévention de la TME du VIH sont non seulement efficaces par
rapport aux autres options thérapeutiques (monothérapie, bithérapie ou bithérapie associée à la réalisation de la césarienne
élective), mais aussi mieux tolérées et devraient par conséquent constituer la stratégie interventionnelle principale.
MOTS CLES: TME du VIH- Trithérapie antirétrovirale- Effets secondaires- Taux d’infection pédiatrique du VIH.
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I- INTRODUCTION
Mother-to child HIV transmission (MTCT) isthe most common aetiology of paediatric HIVinfection throughout the world [1]. The
increasing number of infected women of childbearing
age makes the prevention of MTCT a public health
priority in many African countries where antenatal HIV
seroprevalence ranges between 20 and 40% [2,3]. The
virus may be transmitted during pregnancy, childbirth or
breastfeeding [4]. Where no preventive measures are
taken, the risk of paediatric HIV infection from the
infected mother ranges from 15% to 25% in the
industrialized countries and from 20 to 40% in the
developing countries [2]. Cameroon government
strategic plan for 2006-2010 concerning the prevention
of MTCT has consisted of antiretroviral Nevirapine
monotherapy or bitherapy (Zidovudine and Nevirapine)
during pregnancy for women who are HIV positive or
triple therapy for pregnant women with AIDS [5]. Such
a therapeutic approach in Cameroon has significantly
reduced perinatal transmission over the years from 40%
to values ranging between 6-11% [3].  These values
still remain extremely higher than the 2% vertical
transmission rate in the industrialized countries where
triple antiretroviral therapy, scheduled Caesarean
sections and artificial feeding constitute the main
intervention in preventing MTCT [6]. However, no
definitive data are available regarding the risk of HIV
transmission to the baby according to the mode of
delivery among HIV infected pregnant women receiving
potent antiretroviral therapy. In this study, we intended
to provide evidence that HIV-infected pregnant women
receiving highly active triple antiretroviral therapy without
elective caesarean section which carries risk of increased
morbidity and mortality can be expected to have
significantly lower maternal viral load; with consequently
a lower risk of MTCT.
II- MATERIALS AND METHODS
This prospective and descriptive study was enrolled at
the 4 teaching hospitals (Central Maternity, University
Teaching Hospital, General Hospital and Gynaecologic-
Obstetric & Paediatric Hospital) in Yaoundé
(Cameroon) from January 1, 2006 to December 31,
2008. Sociodemographic variables including the age,
occupation, marital status, religion and regional origin
were collected. Other covariates studied were the
partner’s serostatus, antiretroviral therapy protocol,
baby’s gestational age at birth, gender, birth weight,
placental weight and serostatus. Maternal biological and
immunological variables analyzed to evaluate drug
efficacy and toxicity were the CD4 count, viral load
(VL), fasting blood sugar (FBS), liver enzymes (SGOT,
SGPT), blood urea, alkaline phosphatase (PAL) and
haemoglobin concentration (Hb). A questionnaire
containing the studied variables was filled for each
patient. For each variable, the value before and after
antiretroviral therapy were compared. All the patients
underwent routine antenatal supervision, received
haematinics and 3 doses of sulfadoxine-pyrimethamine
tablets for malaria prophylaxis. Highly active triple
antiretroviral therapy was provided free-of-charge from
28 weeks of gestation to one week post partum when
participants were referred to the HIV/AIDS treatment
centre at Yaoundé General Hospital for follow-up by
one of the researchers. Patients with CD4 count below
250 cells/mm3 received Nevirapine tablet 200mg twice
daily, Lamivudine tablet (150 mg twice daily) and
Zidovudine tablet (300 mg twice daily). Those with CD4
count above 250 cells/ mm3 received Lamivudine (150
mg tablet twice daily), Zidovudine (300 mg tablet twice
daily) and Alluvia® (combination of Lopimavir and
Retonavir) 2 tablets twice daily. This protocol was
approved by the different hospital authorities. 
During labour, vaginal disinfection with cyteal
(hexamidine, chlorhexidine, chlorocresol) was carried
out 4-hourly without rupturing the membranes artificially.
Episiotomy, milking of cord blood, aspiration of the
baby’s upper respiratory airways and instrumental
vaginal delivery were avoided as much as possible and
Caesarean section was performed only for obstetric
indications or when maternal viral load exceeded 1000
copies/ml. All newborns were bathed with diluted cyteal
solution at birth and received nevirapine suspension, 2mg/
kg in a single dose and zidovudine suspension, 4 mg/kg
twice daily for 7 days. The babies were formula-fed
and lactation was suppressed using bromocriptine orally
for 10 days. For the early diagnosis of paediatric HIV
infection, PCR assay, the cost of which was borne by
the mother, was carried out on each baby 8 weeks after
delivery at Centre Pasteur Yaoundé. The sensitivity and
specificity of the real-time PCR assay were both 100%,
with 95% confidence intervals of 93.7% to 100% and
98.3% to 100% respectively [7].
The prevalence of HIV infection in pregnant women in
Cameroon is about 6%. The degree of precision of our
study is 0.05 and the confidence interval is 0.05. By
applying the Lorentz formula, our sample size should
have at least 87 women. Consequently, we recruited
cases in the 4 university hospitals for an optimal follow-
up until our sample size was attained. All the data were
analysed using SAS system for windows. Univariate
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patients who received treatment for at least 8 weeks
had a significant reduction in the viral load with absolute
immunological improvement (Table III). One patient with
an initial viral load of 139,928 copies /ml and a CD4
count level of 296 cells/ mm3 diagnosed HIV-infected
at 34 weeks gestation was treated for only 2.5 weeks
prior to delivery. She was the only patient whose baby
was tested HIV positive giving a paediatric infection rate
of 1.11%. However, antiretroviral therapy has been
associated with adverse effects on lipid metabolism with
possible cardiovascular disease, liver, renal and
haematological toxicity [9,10,14]. Fortunately, short
courses of potent triple antiretroviral therapy in
pregnancy to prevent MTCT suggest that there may be
slight significant adverse effects in the short term. Fasting
blood sugar, SGOT, haemoglobin concentration values
and renal functions before and after antiretroviral
treatments were not significantly impaired (P> 0.05).
The only liver enzymes which was significantly increased
was SGPT (P< 0.05) possibly indicating viral hepatitis
or chemical hepatitis from drug toxicities [9,12,14]. In
addition, the significant increase in post treatment alkaline
phosphatase values (P<0.05) could be more of
trophoblastic than of hepatic origin [15].
Although the benefits of triple antiretroviral therapy for
both mothers and their babies are apparent and cannot
be overemphasized, all antiretroviral drugs should be
prescribed with caution and closely be monitored with
relevant clinical and laboratory indices, especially in
pregnancy.
V- CONCLUSION AND RECOMMENDATIONS
Our results suggest that short courses highly active triple
antiretroviral therapy (at least 8 weeks) from 28 weeks
gestation to prevent HIV MTCT is efficacious compared
to other treatment options and generally safe with minimal
adverse effects. It is associated with such a significantly
low maternal viral load that scheduled Caesarean section
becomes unnecessary. Routine antenatal counseling and
HIV screening, the use of triple antiretroviral therapy in
HIV infected expectant mothers and the strict application
of the preventive obstetric measures in labour as well as
artificial feeding of the newborns appear the ideal
intervention strategy for preventing paediatric HIV
infection in Cameroon. Government subvention for triple
antiretroviral therapy in HIV infected pregnant women
would significantly reduce pediatric HIV infection in
Cameroon 
REFERENCES:
1.    Read JS. Preventing mother to child transmission
of HIV: the role of caesarean section. Sex Transm
Inf 2000; 76: 231-2.
2.   Unicef 1999. Progress of nations. Available from:
http://www.unicef.org/pon99.
3.  Ahidjio Ajouba, Tene G, Cunin P, Menu E,
Anfumbom, Thonom J, et al. Low rate of mother-
to-child transmission of HIV-1 after nevirapine
intervention in a pilot Public health program in
Yaoundé, Cameroon.  Acquir Immune Defic Syndr
2003; 34(3): 274-80.
4.   UNAIDS Q & As. Mother to child transmission
(MTCT) of HIV. Background briefs 1999, 19p.
5.    Guide de poche pour la prévention de la transmission
mère-enfant du VIH. Ministère de la Santé  Publique
2006, République du Cameroun.
6.      Achievements in public health: Reduction in perinatal
transmission of HIV infection- United States, 1985-
2005. Available from:
      http://www.cdc.gov/mmwr/preview/mmwrhtml/
mm5521a3.htm26/6/2007
7.   Rouet F, Didier K, Ekouevi, Chaix ML, Burgard
M, Inwoley A, et al. Transfer and evaluation of an
automated low coast Real-Time Reverse
Transcription-PCR test for diagnosis and monitoring
of human immunodeficiency virus type I infection in
a West African Resource limited Setting. J Clin
Microbiol 2005; 43(6): 2709-17.
8.   Tejiokem MC, Nerrienet E, Tene G, Mena E, Barré-
Sinoussi F, Ayouba A. Prévention de la transmission
mère-enfant (TME) du VIH-1: l’exemple du
Cameroun. Med Mal Infect 2004 ; 34 : S57-S60.
9.   Makamche MF, Soares E, Alemnji G, Mbuagbaw
        J, Lumngwena E, Penlap V, et al. Effects of various
antiretroviral regimens on lipid metabolism and liver
function among HIV/AIDS patients in Yaoundé,
Cameroon. Health Sci Dis 2007; 8(4): 4-11.
10. Polly Clayden. Nevirapine, pregnancy and adverse
events. HIV Treat Bull 2004; 5(3): 1-3.
11.Njom Nlend A, Tchendjou Takam P, Tsague DL,
Gake Bouba, Nga R and the North PMTCT group.
Preventing Mother-to-child transmission of HIV in
a low antenatal coverage area: the North Province
of Cameroon. Clin Mother Child Health 2006; 3(2):
541.
Efficacy of highly active triple antiretroviral therapy in preventing mother-to-child HIV transmission
 
1080
Clinics in Mother and Child Health Vol 6, N° 2,  December 2009
12.  Lallemant M, Gonzague Jourdain, Le Coeur S,
Mary JY, Ngo Giang Huong N, Suporn
Koetsawang, et al. Single dose perinatal nevirapine
plus standard Zidovudine to prevent Mother-to-
child transmission of HIV-1 in Thailand. N Engl J
Med 2004; 351(3): 217-28.
13.  Dabis F, Leroy V, Castetbon K, Spira R, Newell
ML, Salomon R. Preventing mother-to child
transmission of HIV-1 in Africa in the year 2000.
      AIDS 2000; 14(8): 1017-26.
14.  Bagnis CI, Tezenas Du Montcel S, Fonfrede M,
Jaudon MC, Thibaut V, Carcelain G, et al. Changing
electrolyte and acido-basic profile in HIV-infected
patients in the HAART era. Nephron Physiol 2006;
103: 131-8.
15. Philipp EE, Barnes J, Newton M. Scientific
Foundations: Obstetrics and gynaecology; third
edition; 1986, 499 p.
Fomulu J.N. et al.
